News Quantified

CYCC – cyclacel pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ALT, CYCC and DB among pre-market losers [Seeking Alpha]

MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers [Seeking Alpha]

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future [Yahoo! Finance]

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

-4.3%

BEAT

-35.5%

MISS

-5.1%

BEAT

-1.2%

BEAT

Form RW Cyclacel Pharmaceuticals

Form 10-K/A Cyclacel Pharmaceuticals For: Dec 31

Form 8-K Cyclacel Pharmaceuticals For: Apr 26

Form S-1/A Cyclacel Pharmaceuticals

Form S-1/A Cyclacel Pharmaceuticals

Top News Gainers

4/20 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease 34.0%

12/9 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias 19.3%

9/4 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference 10.5%

10/31 Form 8-K Cyclacel Pharmaceuticals For: Oct 28 10.3%

9/23 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference 7.2%

8/13 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.150 ActVsEst 0.040 - Beat 6.4%

3/18 Form 8-K Cyclacel Pharmaceuticals For: Mar 18 5.4%

3/17 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.3%

2/12 Form SC 13G Cyclacel Pharmaceuticals Filed by: RENAISSANCE TECHNOLOGIES LLC 4.2%

10/13 Here's Why We're Watching Cyclacel Pharmaceuticals's (NASDAQ:CYCC) Cash Burn Situation [Yahoo! Finance News] 3.7%

Top News Decliners

4/20 Form 8-K Cyclacel Pharmaceuticals For: Apr 19 -48.5%

3/13 Form S-1 Cyclacel Pharmaceuticals -27.1%

1/10 Form 8-K Cyclacel Pharmaceuticals For: Jan 10 -12.1%

2/26 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results -11.7%

11/13 Form 10-Q Cyclacel Pharmaceuticals For: Sep 30 -11.3%

7/16 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%

11/18 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $0.50 price target on the stock. -10.2%

2/3 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference -9.6%

5/31 Form 4 Cyclacel Pharmaceuticals For: May 29 Filed by: Spiegel Robert J. -9.2%

9/17 Form PRE 14A Cyclacel Pharmaceuticals For: Oct 28 -9.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day